Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) Income towards Parent Company (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Income towards Parent Company for 3 consecutive years, with -$20.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Income towards Parent Company fell 29.09% to -$20.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$83.9 million, a 35.39% decrease, with the full-year FY2025 number at -$83.9 million, down 28.27% from a year prior.
  • Income towards Parent Company was -$20.8 million for Q4 2025 at Artiva Biotherapeutics, up from -$21.5 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of -$11.4 million in Q4 2023 to a low of -$21.5 million in Q3 2025.
  • A 3-year average of -$16.9 million and a median of -$16.3 million in 2024 define the central range for Income towards Parent Company.
  • Biggest YoY gain for Income towards Parent Company was 29.09% in 2025; the steepest drop was 46.71% in 2025.
  • Artiva Biotherapeutics' Income towards Parent Company stood at -$11.4 million in 2023, then crashed by 41.31% to -$16.1 million in 2024, then fell by 29.09% to -$20.8 million in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Income towards Parent Company are -$20.8 million (Q4 2025), -$21.5 million (Q3 2025), and -$21.2 million (Q2 2025).